BIT/1MRNA (BIT/1MRNA)

Borsa Italiana: BIT/1MRNA · EUR

€168

-5.84 (-3.4%)· Recorded snapshot

Market cap	74.5B
Revenue (ttm)	2B
Net income (ttm)	-2.8B
EPS (ttm)	-€7.20
Volume	27,213

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2B
Net income (ttm): -2.8B
EPS (ttm): -€7.20
Market cap: 74.5B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-39

P25 n/aP50 n/aP75 n/a

ROIC-76

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BIT/1MRNA indicators

Market & fundamental data

Available fields

177

Groups with data

Currency

USD

Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	IT
Earnings date	2026-11-06
Employees	4,700
Employees change	-1,100
Employees growth	-18.97%
Enterprise value	EUR 69.5B
Exchange	Borsa Italiana
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2010
Industry	Biotechnology
Is primary listing	No
ISIN number	US60770K1079
Last earnings date	2026-07-31
Last refreshed	2026-10-28
Market cap	EUR 74.5B
Next earnings date	2026-11-06
Price	EUR 168.16
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-02
Symbol	bit/1MRNA
Website	https://www.modernatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.28%
EV/Sales	34.74x
FCF / EV yield	-1.57%
FCF yield	-1.46%
P/B ratio	12.59x
P/S ratio	38.21x
Price / tangible book value	12.9x
Sector forward P/E	16.78x
Sector P/E	20.93x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-109.34%
EBITDA margin	-98.52%
Gross margin	-66.02%
Operating margin	-109.34%
Pretax margin	-138.55%
Profit margin	-141.43%
Profit per employee	EUR -586,823
Revenue per employee	EUR 414,929
ROA	-13.26%
ROA (5Y)	6.72%
ROCE	-28.91%
ROE	-39%
ROE (5Y)	22.02%
ROIC	-75.99%
ROIC (5Y)	40.43%
SBC / revenue	20.74%
Tax / revenue	2.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth quarters	1
Net income growth years	2
Revenue growth	-27.62%
Revenue growth (Q)	2.11%
Revenue growth (QoQ)	-62.72%
Revenue growth 3Y	-40.64%
Revenue growth 5Y	-20.51%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -149.7M
Depreciation and amortization	EUR 216.6M
EBIT	EUR -2.1B
EBITDA	EUR -1.9B
EPS	EUR -7.20
Financing cash flow	EUR 534.8M
Free cash flow	EUR -1.1B
Free cash flow minus SBC	EUR -1.5B
Gross profit	EUR -1.3B
Income taxes	EUR 56M
Investing cash flow	EUR 792.1M
Net borrowing	EUR 519.6M
Net cash flow	EUR 387.8M
Net income	EUR -2.8B
Operating cash flow minus SBC	EUR -1.3B
Operating income	EUR -2.1B
Revenue	EUR 2B
Stock-based compensation	EUR 404.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.62
Book value per share	EUR 14.83
Debt / equity	0.19
Goodwill	EUR 46.7M
Interest coverage	-58
Long-term assets	EUR 4.4B
Long-term liabilities	EUR 1.4B
Net cash (debt)	EUR 4.9B
Net cash / market cap	6.6%
Net cash growth	-16.87%
Net debt / equity	-0.83
Piotroski F-Score	2
Property, plant and equipment	EUR 2.5B
Shareholders' equity	EUR 5.9B
Tangible book value	EUR 5.8B
Tangible book value per share	EUR 14.48
Total assets	EUR 9.6B
Total cash	EUR 4.5B
Total debt	EUR 1.1B
Total liabilities	EUR 3.7B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	EUR 5.2B
Current liabilities	EUR 2.3B
Current ratio	2.29
Inventory turnover	14.23
Net working capital	EUR -1.6B
Quick ratio	2.07
Working capital	EUR 2.9B
Working capital turnover	0.49

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.94%
Shareholder yield	-1.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 67.73
1D price change	-3.36%
1M price change	32.41%
1M total return	32.41%
1W price change	3.28%
1W total return	3.28%
1Y price change	598.63%
1Y return CAGR	599.56%
1Y total return	598.63%
20-day SMA	EUR 145.75
200-day SMA	EUR 59.72
3M price change	162.67%
3M total return	162.67%
3Y price change	73.77%
3Y return CAGR	20.22%
3Y total return	73.77%
50-day SMA	EUR 107.91
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 184.00
52-week high date	2026-09-29
52-week low	EUR 19.38
52-week low date	2025-11-21
6M price change	284.94%
6M total return	284.94%
All-time high	EUR 201.10
All-time high date	2022-12-14
All-time low	EUR 19.38
All-time low date	2025-11-21
Average true range (ATR)	EUR 11.08
Average volume	33.8K
Change from 52-week high	-8.61%
Change from 52-week low	767.7%
Change from all-time high	-16.38%
Change from all-time low	767.7%
Change from open	-1.81%
Day's gap	-1.57%
Dollar volume	EUR 4.6M
High price	EUR 172.66
Low price	EUR 162.70
Monthly RSI	77.27
Open price	EUR 171.26
Position in 52-week range	54.82%
Previous close	EUR 174.00
Price vs 150-day SMA	148.27%
Price vs 20-day SMA	15.37%
Price vs 200-day SMA	181.6%
Price vs 50-day SMA	55.83%
Relative volume	0.81
RSI	67.95
Sharpe ratio	1.84
Sharpe ratio (3Y)	0.51
Sortino ratio	6.06
Sortino ratio (3Y)	1.15
Volume	27.2K
Weekly RSI	81.4
YTD price change	540.85%
YTD total return	540.85%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	372M
Shares change (QoQ)	0.76%
Shares change (YoY)	1.94%
Shares held by insiders	6.74%
Shares held by institutions	80.56%
Short ratio	1.6 days

Deeper analysis on BIT/1MRNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BIT/1MRNA report

Is a complete BIT/1MRNA research report available?

No complete published report is available for bit/1MRNA (BIT/1MRNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BIT/1MRNA (BIT/1MRNA)

Price

Financial snapshot

Fair-value bridge

Latest news · BIT/1MRNA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BIT/1MRNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BIT/1MRNA

Frequently asked questions